Dave Stack, Pacira BioSciences CEO
Flexion heads to the discount aisle for a $450M+ merger with Pacira
Once riding high with its non-opioid drug for knee pain, Flexion was at the center of the M&A rumor mill for a 10-figure buyout. Years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
